Komori
Almado (4932) · RiskRestated

Regulatory compliance for cosmetics and health foods

First written in FY2021. 2 of 3 entries say "Restated". Latest entry: FY2023.

3entries
3years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2021 – FY20232021: 120212022: 120222023: 12023
Same theme, other companies
Risk of Maintaining Licenses to Manufacture and Market Cosmetics and Quasi-DrugsA theme 7 companies write about · 7 as a headwind · 0 as a tailwind

4 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2023RestatedAnnual report

    「The Act contains provisions governing advertising for cosmetics and quasi-drugs, prohibiting the promotion of false or potentially misleading information and unapproved indications or effects. Accordingly, the Company has established review rules, including internal advertising guidelines, and conducts prior reviews.」

    The Company continues to disclose prior reviews based on relevant laws and regulations, licences and permits, and advertising guidelines. The licences are valid through 26 December 2027, and the Company states that there have been no violations.
  2. FY2022RestatedAnnual report

    「The Act contains provisions governing advertising for cosmetics and quasi-drugs, prohibiting the promotion of false or potentially misleading information and unapproved indications or effects. Accordingly, the Company has established review rules, including internal advertising guidelines, and conducts prior reviews.」

    The Company continues to disclose its response to applicable laws and regulations concerning cosmetics and health foods, licence renewals and prior reviews under its advertising guidelines.
  3. FY2021First statedAnnual report

    「The Act contains provisions governing advertising for cosmetics and quasi-drugs, prohibiting the promotion of false or potentially misleading information and unapproved indications or effects. Accordingly, the Company has established review rules, including internal advertising guidelines, and conducts prior reviews.」

    The Company obtained licences to manufacture and sell cosmetics and to manufacture and sell quasi-drugs, which were stated to be valid through 26 December 2022.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Almado's next results are scheduled for 2026-11-13. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.